Abstract
Myasthenia gravis was first described 300 years ago, but today is one of the most well characterised autoimmune diseases. Whilst its prognosis was previously grave, cholinergic and immunomodulatory therapy has greatly improved survival over the last two decades. Improved recognition of the condition and effective therapy has transformed this previously debilitating and often fatal condition into an eminently treatable and reversible condition.
[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]
References
- Willis T. De anima brutorum. in Theatro Sheldonia Oxford, England, 1672.
- Robertson NP, Deans J, Compston DA. Myasthenia Gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998; 65: 492-496.
- Weizer JS, Lee AG, Coats DK. Myasthenia gravis with ocular involvement in older patients. Can J Ophthalmol 2001; 36: 26-33.
- Kleiner-Fisman G, Kott HS. Myasthenia gravis mimicking stroke in elderly patients. Mayo Clin Proc 1998; 73: 1077-1078.
- Aarli JA. Late-onset myasthenia gravis: a changing scene. Arch Neurol 1999; 56: 25-27.
- Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci 1981; 377: 652-669.
- Ing EB, Ing SY, Ing T, et al; The complication rate of edrophonium testing for suspected myasthenia gravis. Can J Ophthalmol 2000; 35: 141-144.
- Okun MS, Charriez CM, Bhatti MT, et al; Asystole induced by edrophonium following beta blockade. Neurology 2001; 57: 739.
- Oh SJ, Cho HK. Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis. Muscle Nerve 1990; 13: 187-191.
- Diamond S, Schear HE, Leeds MF. Pseudo-internuclear oculomotor ophthalmoplegia secondary to Guillain-Barre polyneuritis simulating myasthenia gravis in an air transport pilot. Avi Spa Environ Med 1975; 46: 204-207.
- Mulder DW, Lambert EH, Eaton LM. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 1959; 9: 627-631.
- Hoch W, McConville J, Helms S, et al; Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8.
- Oh S, Kim DE, Kuruoglu R, et al; Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992; 15: 720-724.
- de Perrot M, Licker M, Spiliopoulos A. Factors influencing improvement and remission rates after thymectomy for myasthenia gravis. Respiration 2001; 68: 601-605.
- Nieto IP, Robledo JP, Pajuelo MC, et al; Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg 1999; 67: 1568-1571.
- Mayer SA. Intensive care of the myasthenic patient. Neurology 1997; 48 (Suppl. 5): S70-S75.
- Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122-8.
- Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291-298.
- Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974; 290: 81-84.
- Kornfeld P, Ambinder EP, Mittag T, et al; Plasmapheresis in refractory generalized myasthenia gravis. Arch Neurol 1981; 38: 478-81.
- Achiron A, Barak Y, Miron S, et al; Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 2000; 23: 551-555.
- Gajdos P, Chevret S, Clair B, et al; Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41: 789-96.
- Owen HG, Brecher ME. Atypical reactions associated with the use of angiotensin converting enzyme inhibitors and apheresis. Transfusion 1994; 34: 891-894.
- Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50: 1778-83.
- Gajdos P, Outin H, Elkharrat D, et al; High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 1: 406-7.
- Said G, editor: Treatment of neurological disorders with intravenous immunoglobulins. Martin Dunitz Ltd., London, 2000.
Request Permissions
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center’s (CCC) Marketplace website by clicking the button below:
